Last updated on: 12/16/2008 | Author:

Olivier Rabin, PhD Biography

Science Director of the World Anti-Doping Agency (WADA)
Con to the question "Should Performance-Enhancing Drugs Be Accepted in Sports?"

“Doctors are in a very privileged position to inform patients of the risks associated with performance enhancing drugs. Anabolic steroids, human growth hormone, and other substances can lead to cardiovascular risks, kidney problems, mood swings, and many other health disorders. They can have an impact on sexual aspects of people’s lives as well as on personality. They have an enormous impact on their private lives. Many risks are misrepresented by the manufacturers of those products, by people who are selling them in gyms, or by friends who really don’t know the risks. Often, abusers simply don’t know or understand what the risks are, while others may be in denial about them or play them down. They see the immediate benefit of taking the drugs without seeing the long-term toxicity and impact on health. I believe the primary role of physicians, when they identify such patients, is to tell them look, between you and me, you’re taking this substance, but do you know the risks?”

“To Dope or Not to Dope: That Is the Ethical Question -- Part 2: An Expert Interview With Dr. Olivier Rabin,” Medscape Orthopaedics & Sports Medicine, Oct 19, 2006

Involvement and Affiliations:
  • Science Director, World Anti-Doping Agency (WADA), 2002-present
  • Manager, Research and Business Development, Beaufour-IPSEN Pharma, 1994-2002
  • Principal Investigator, Pharmacology and Toxicology, National Institutes of Health, US Department of Health and Human Services, 1990-1994
  • Former Researcher, Institut National de la Santé et de la Recherche Médicale, France
  • PhD, Fundamental and Applied Toxicology, Université Pierre et Marie Curie
  • Degree unknown, Biomedical Engineering, Université Pierre et Marie Curie
  • Attended the University College London, University of London
  • None found